Atlas Trials

Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD

Clinical trial NCT04626128 · COMPLETED

Trial details

NCT number
NCT04626128
Sponsor
Clearside Biomedical, Inc.
Status
COMPLETED
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Neovascular Age-related Macular Degeneration
Start date
2020-12-15
Primary completion
2022-10-13
Enrollment
27

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.